We performed immunohistochemistry on skin sections to assess TGM2 expression and localization, and protein biochemistry of both systemic sclerosis–derived and healthy control dermal fibroblasts to assess TGM2 expression, function, and extracellular matrix deposition in the presence of TGM2 inhibiting and transforming growth factor (TGF)‐β neutralizing antibodies and a small‐molecule inhibitor of the TGF‐βRI kinase. Here, TGM2 is linked to systemic sclerosis.